Astellas Pharma Inc: Prostatic Neoplasms trials

The registry lists 53 Prostatic Neoplasms studies with Astellas Pharma Inc as lead sponsor. 5 are open to participants now and 11 have results posted.

Phase 1 15Phase 2 19Phase 3 4Phase 4 5No phase 13(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Learn How Enzalutamide, Apalutamide and Bicalutamide Affect the Way Fezolinetant is Processed in Men With Prostate CancerRecruitingNCT07783282Phase 1
• A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate CancerRecruitingNCT07339267Phase 1
• A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate CancerRecruitingNCT07005154Phase 2
• Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate CancerRecruitingNCT05997615Phase 1
• A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate CancerRecruitingNCT04729114Phase 1
• A Study of ELIGARD® in Hormone-dependent Prostate Cancer PatientsCompletedNCT03035032Phase 4Results posted
• Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate CancerCompletedNCT02918968Phase 4Results posted
• A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active SurveillanceCompletedNCT02799745Phase 2Results posted
• A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel TreatmentTerminatedNCT02441517Phase 4Results posted
• An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer ParticipantsCompletedNCT02294461Phase 3Results posted
• A Study to Assess the Benefit of Treatment Beyond Progression With Enzalutamide in Men Who Are Starting Treatment With Docetaxel After Worsening of Their Prostate Cancer When Taking Enzalutamide AloneCompletedNCT02288247Phase 3Results posted
• A Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate CancerCompletedNCT02116582Phase 4Results posted
• A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer PatientsCompletedNCT01650194Phase 2Results posted
• A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100CompletedNCT01534052Phase 2Results posted
• A Study to Test if Enzalutamide is Effective and Safe in Prostate Cancer Patients Who Have Never Had Hormone TherapyCompletedNCT01302041Phase 2Results posted
• A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate CancerCompletedNCT01288911Phase 2Results posted
• Experiment to Assess Preferences for Novel Hormonal Therapy and Androgen-deprivation Therapy in Prostate Cancer PatientsCompletedNCT06500741
• Non-Interventional Study to Establish Consensus on Management of Metastatic Hormone-Sensitive Prostate Cancer PatientsCompletedNCT06452212
• Survey Based Discrete Choice Experiment Study in Prostate Cancer (DECIDER) StudyCompletedNCT05381311
• A Study to Evaluate the Effect of Multiple Doses of Enzalutamide on the Pharmacokinetics of Substrates of P-glycoprotein (Digoxin) and Breast Cancer Resistant Protein (Rosuvastatin) in Male Subjects With Prostate CancerCompletedNCT04094519Phase 1
• A Non-Interventional Study to Evaluate Time to Event and Healthcare Resource Utilisation for Prostate Cancer Participants Throughout the Disease Trajectories Until Progression or DeathCompletedNCT03619980
• A Registry Based Study Evaluating Overall Survival and Treatment Length in mCRPC Patients Treated With Enzalutamide in SwedenCompletedNCT03328364
• A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical StudyActive, not recruitingNCT02960022Phase 2
• Long-Term Specified Drug Use-Results Survey for Xtandi CapsuleCompletedNCT02669771
• European Observational Study of Enzalutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)CompletedNCT02495974
• Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC)CompletedNCT02380274
• A Study to Evaluate How Daily Dosing With Enzalutamide Affects the Metabolism of Caffeine and Dextromethorphan in Men With Prostate CancerCompletedNCT02225093Phase 1
• An Observational Study Looking at How Well the Drug Eligard Works and How Well it is Tolerated by the Body of Patients With Advanced Prostate Carcinoma in the Russian FederationCompletedNCT02128334
• A Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based ChemotherapyCompletedNCT02124668Phase 2
• A Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-resistant Prostate Cancer and Men With Metastatic Prostate CancerCompletedNCT02066961
• A Study to Compare the Effect of ASP3550 With Goserelin in Patients With Prostate CancerCompletedNCT01964170Phase 3
• A Study in Patients With Metastatic Prostate Cancer to Assess How the Drug Eligard®, Affects Certain Markers in Blood and Urine, Which Are Indicators for the DiseaseTerminatedNCT01933022Phase 4
• A Study to Compare Capsule and Tablet Forms of MDV3100 (Enzalutamide) After Administration of a Single Set Dose Under Fasted Conditions in Healthy Male SubjectsCompletedNCT01911741Phase 1
• Drug-drug Interaction Study With MDV3100 and a Cocktail of SubstratesCompletedNCT01911728Phase 1
• Relative Bioavailability Study of Enzalutamide in Prostate Cancer PatientsCompletedNCT01902251Phase 1
• Observational, Non-interventional, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer PatientsCompletedNCT01793077
• A Study to Evaluate the Safety and Efficacy of Enzalutamide in Chemotherapy-Naïve, Symptomatic Patients With Metastatic Castration-Resistant Prostate CancerWithdrawnNCT01663415Phase 2
• Provide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based ChemotherapyApproved for marketingNCT01606982
• Phase I/II Study of ASP9521 in Castrate-Resistant Prostate Cancer (CRPC) PatientsTerminatedNCT01352208Phase 1/2
• A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer PatientsCompletedNCT01284920Phase 1/2
• Study to Find Maintenance Dose for Periodic Administration of ASP3550CompletedNCT01261572Phase 2
• A Study to Determine the Maximum Tolerated Dose of ASG-5ME in Subjects With Castration-Resistant Prostate CancerCompletedNCT01228760Phase 1
• An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155CompletedNCT00818480Phase 2
• Retrospective, Non-interventional Study of Depo-Eligard®.CompletedNCT00811876
• A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)CompletedNCT00739453Phase 1
• Phase II Study of ASP3550 in Patients With Prostate CancerCompletedNCT00568516Phase 2
• AGS-1C4D4 in Patients With Advanced Hormone Refractory Prostate CancerCompletedNCT00519233Phase 1
• An Open-Label Study of YM155 + Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid TumorsCompletedNCT00514267Phase 1/2
• A Phase IIIb Study of Intermittent Versus Continuous Hormone Deprivation Treatment With ELIGARDCompletedNCT00378690Phase 3
• A Study for the Treatment of Hormone Refractory Prostate Cancer (HRPC) in Patients Previously Treated With ChemotherapyCompletedNCT00257478Phase 2
• YM598 in Patients With Rising PSA After Initial Therapy for Localized Prostate CancerTerminatedNCT00050297Phase 2
• YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone TherapyTerminatedNCT00048659Phase 2
• Study Using CP-461 to Treat Advanced Prostate CancerCompletedNCT00036075Phase 2